Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | HTR6 | P50406 | 8/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | PPME1 | Q9Y570 | 3/20 | 0.34 |
| ▸ | APEH | P13798 | 1/20 | 0.34 |
| ▸ | PARL | Q9H300 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2411881 | 0.99 | BRD4 (0.36) | BRD4HTR6DRD2DRD3PPME1 | |
| SCHEMBL1763431 | 0.84 | HTR6 (0.43) | BRD4HTR6DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2407082 | 0.83 | HTR6 (0.42) | BRD4HTR6DRD2DRD3 | |
| SCHEMBL28642111 | 0.81 | HTR6 (0.39) | HTR6DRD2DRD3PARLCYP3A4 | |
| SCHEMBL2416543 | 0.81 | KDM4E (0.38) | HTR6 | |
| SCHEMBL1763037 | 0.81 | HTR6 (0.37) | BRD4HTR6DRD2DRD3PARL | |
| Hydrochloric Acid SCHEMBL2409398 | 0.80 | HTR6 (0.37) | BRD4HTR6DRD2DRD3PARL | |
| SCHEMBL1580766 | 0.80 | HTR6 (0.43) | HTR6DRD2DRD3PARLCYP3A4 | |
| Hydrochloric Acid SCHEMBL1156349 | 0.78 | HTR6 (0.42) | HTR6DRD2DRD3PARLCYP3A4 | |
| SCHEMBL1580456 | 0.77 | MET (0.38) | HTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | BRD4 4861/4885HTR6 1727/4885DRD2 2278/4885 |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | BRD4 4861/4885HTR6 1727/4885DRD2 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.